NC Medicaid covers GLP‑1s for weight loss, with prior authorization

NC Medicaid covers GLP-1 drugs for weight management with prior approval; on the October 2026 Preferred Drug List, Wegovy (pen and tablet), Wegovy HD, Foundayo and the Zepbound pen/KwikPen are preferred, and Saxenda and generic liraglutide are non-preferred.1234

Since Dec. 12, 2025, NC Medicaid has used the weight-management prior approval criteria that took effect Aug. 1, 2024. Approval is for 6 months at first and 12 months on renewal. A draft revision posted for 45-day public comment in 2026 would add Wegovy HD and Foundayo and require an in-person visit every 6 months; it was still marked draft when we checked.4567

• Adults 18+: BMI >= 30, or BMI >= 27 with at least one weight-related condition (such as high blood pressure, type 2 diabetes, sleep apnea, heart disease or high cholesterol)
• Ages 12 to 17: BMI at or above the 95th percentile, BMI >= 30, or BMI at or above the 85th percentile with a severe weight-related condition
• Baseline weight and BMI measured within 45 days of the request
• Ongoing lifestyle changes, including structured nutrition and physical activity
• Not used together with another GLP-1 drug; no FDA-labeled contraindications
• A non-preferred drug needs a 3 to 6 month trial of the preferred drug, or a documented reason the preferred drug cannot be used
• Renewal: adults keep off at least 5% of starting weight (adolescents: more than 4% drop in BMI), or the prescriber documents a significant maintained loss

Coverage for other uses the FDA has approved:

• Wegovy (injection), cardiovascular risk reduction in adults with established cardiovascular disease and obesity or overweight: Covered with prior authorization48
• Wegovy (injection), noncirrhotic MASH with moderate to advanced liver fibrosis in adults: Covered with prior authorization48
• Zepbound, moderate to severe obstructive sleep apnea in adults with obesity: Covered with prior authorization48

What changed, and when:

CMS BALANCE model: CMS says state Medicaid agencies can join the BALANCE Model from May 2026 through Jan. 1, 2027, but its model page lists no participating states, and we found no NC Medicaid announcement about joining.11

The State Health Plan stopped covering GLP-1 drugs such as Wegovy and Saxenda for weight loss on April 1, 2024, after a vote by its Board of Trustees. An October 2025 agreement with CVS Caremark lets the Plan negotiate with GLP-1 makers to potentially restore coverage, but we found no official notice that coverage has returned.121314

Pharmacy benefit: NC Department of State Treasurer; pharmacy benefit manager CVS Caremark.

Marketplace (ACA) plans: North Carolina's benchmark plan is Blue Cross NC's Blue Options PPO. Its CMS summary for 2025 to 2027 lists weight loss programs as not covered, and its drug-count table has no anti-obesity class. The plan booklet CMS posts names FDA-approved drugs for long-term obesity treatment among covered prescription drugs. We could not confirm whether marketplace plans must cover these drugs.1819

On the October 2026 Preferred Drug List, the Ozempic pen, Mounjaro pen, Trulicity pen, Victoza pen and Byetta pen are preferred for diabetes, and Rybelsus, the Ozempic tablet, Bydureon BCise and generic liraglutide and exenatide are non-preferred; clinical criteria apply to the whole class.13

In 2025, NC Medicaid paid for 483,131 GLP-1 prescriptions, $588.9 million before rebates: 43 per 1,000 residents, against 32 across the states and DC, 12th of 51.69 It reimbursed 9 GLP-1 products that year. Every state, ranked.

CMS hides counts under 11 in a quarter, so 29 rows count as zero here and the totals are a floor.

Part D still excludes drugs used for weight loss alone: the Part D drug definition excludes drugs and uses Medicaid may exclude under SSA §1927(d)(2), which lists agents used for weight loss. Part D plans can cover GLP-1s for type 2 diabetes, MACE risk reduction (Wegovy), moderate-to-severe obstructive sleep apnea (Zepbound) and noncirrhotic MASH with fibrosis (Wegovy). For weight loss alone, the Medicare GLP-1 Bridge demonstration (July 1, 2026 – Dec 31, 2027) gives eligible Part D enrollees Foundayo, Wegovy or Zepbound KwikPen for a $50 monthly copay, outside the Part D benefit. The BALANCE Model's Part D component is not launching in 2027.4445353631392434

• Medicare GLP-1 Bridge (demonstration) (active, from 2026-07-01): Runs July 1, 2026 to December 31, 2027 (extended). Outside the Part D benefit: $50 copay per one-month supply (28 or 30 days), Part D deductible does not apply, the copay does not count toward TrOOP, no low-income subsidy. Covers Foundayo, Wegovy (injection or tablet) and Zepbound KwikPen only (not Zepbound single-dose vials or pens). Eligibility: age 18+ and, when starting GLP-1 therapy, BMI ≥35; or BMI ≥30 with heart failure with preserved ejection fraction, uncontrolled hypertension, or CKD stage 3a+; or BMI ≥27 with prediabetes, prior heart attack or stroke, or symptomatic peripheral artery disease. People with type 2 diabetes, moderate-to-severe sleep apnea or fatty liver disease are not eligible (their Part D plan may cover GLP-1s for those conditions). Prior authorization required; valid through Dec 31, 2027 unless the patient changes GLP-1s.3132332439404142433837
• BALANCE Model — Medicare Part D component (not launching in 2027; future implementation described by CMS only as 'potential'): Originally announced to launch in Part D in January 2027. CMS's BALANCE page FAQ now refers to 'the BALANCE Model not launching in Medicare in 2027' and extends the Bridge through Dec 31, 2027 to collect data 'ahead of potential implementation of BALANCE in Part D'. No new start date is published.262824

In 2024, Medicare Part D drug plans paid for 836,270 GLP-1 claims from prescribers in North Carolina, $1.05 billion in total drug cost.70

The lowest price among the programs that ship to every state is WellMedr: $492 for 12 months ($41 a month); $99 month to month, fees in.74 Includes a sale seen on November 5, 2026; the price returns to the standing price when it ends. The cheapest programs, ranked, or every program, ranked on our score.

Prices are what each program charged at its own checkout, fees in, with the total due for the plan length first. Compounded GLP-1s are prepared by a pharmacy to a prescription, and they are not FDA-approved; the section on compounding explains what that means.

We may earn a commission when you sign up through some links. It never changes our order or scores. How we make money

29 more programs we rank ship to fewer than 50 states, or don’t say how many. We don’t record which states they leave out, so check North Carolina on their sites: Embody, Collective, SnagRx, Enhanced, Direct Meds, Gala Health, GobyMeds, CoreAge Rx, Maximus Tribe, Brightmeds, SkinnyRx, Willow, Strut Health, Enhance MD, LumiMeds, VivioMD, MEDGm, MyDrHank, Zevay, LevelsRx, Hume Care, ReadyRx, Hers, Luvo Health, Remedy Meds, Hims, DudeMeds, G-Plans and Found.

The makers also sell some brand-name GLP-1s for cash, at the same price in every state, with a prescription:

These are standing prices. The Zepbound and Wegovy rankings list each dose and the terms of each offer.

Compounded GLP-1s are prepared by a pharmacy to a prescription. They are not FDA-approved: the FDA doesn’t review their safety, effectiveness or quality before they’re sold, and they are not the same as Wegovy or Zepbound. Formulas can differ from one pharmacy to the next, and some add ingredients such as vitamin B12.7576 Compounding pharmacies are licensed and inspected by state boards of pharmacy; outsourcing facilities (503B) also register with the FDA and are inspected by it. The FDA can issue warning letters when either breaks rules on safety or sterility.

The FDA’s register lists 1 outsourcing facilities (503B) in North Carolina, as of November 6, 2026; 0 show no inspection date and 1 were issued a Form 483.71

FDA warning letters naming a GLP-1, sent to a company in North Carolina:72